NewAmsterdam Pharma Co N.V. Earnings Per Share Disclosure
Note 13. Net Loss per Ordinary Share
Basic and diluted net loss per ordinary share was calculated as follows:
|
|
Year ended December 31, |
|
|||||||||
(In thousands of USD, except share and per share amounts) |
|
2025 |
|
|
2024 |
|
|
2023 |
|
|||
Net loss |
|
|
(203,819 |
) |
|
|
(241,598 |
) |
|
|
(176,937 |
) |
Weighted average ordinary shares outstanding, basic and diluted |
|
|
118,424,231 |
|
|
|
94,358,067 |
|
|
|
82,161,956 |
|
Net loss per ordinary share, basic and diluted |
|
|
(1.72 |
) |
|
|
(2.56 |
) |
|
|
(2.15 |
) |
The following potentially dilutive securities have been excluded from the computation of diluted weighted-average ordinary shares outstanding as they would be anti-dilutive:
|
|
Year ended December 31, |
|
|||||||||
|
|
2025 |
|
|
2024 |
|
|
2023 |
|
|||
Stock options |
|
|
20,625,368 |
|
|
|
19,029,056 |
|
|
|
15,783,509 |
|
Restricted share units |
|
|
728,283 |
|
|
|
143,002 |
|
|
|
— |
|
Outstanding warrants |
|
|
2,490,104 |
|
|
|
2,632,581 |
|
|
|
4,017,221 |
|
Total |
|
|
23,843,755 |
|
|
|
21,804,639 |
|
|
|
19,800,730 |
|
Want the next NewAmsterdam Pharma Co N.V. earnings per share disclosure the moment it drops?
Set a Sentinel and we'll alert you the moment NewAmsterdam Pharma Co N.V.'s next filing hits EDGAR. No credit card, your email never gets sold.
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.